Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

25 November 2020
Pharma

Visiongain has published a new report on Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab, Cetuximab, Follitropin Alfa, Somatropin, Dornase Alfa). PLUS Regional Market Analysis AND COVID-19 Recovery Scenarios.

Global biosimilars market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2023. Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

COVID-19 Impact on Biosimilars Market
The COVID-19 pandemic has a significant impact on the biosimilars market worldwide. There will be slight decrease in growth rate due to the COVID-19 outbreak, but we expect it will be temporary. Visiongain expect that the market will grow at lucrative rate from 2021 due to the growing demand for cost-effective biosimilar drugs and patent expiry of biologics during the forecast period 2021-2023.

The unmet medical need emerged out unexpectedly and the result was a very high demand from the market; leading to severe drug shortages and demand for less expensive drugs. Biopharmaceutical companies are expected to focus on R&D, new product launches, and strengthening of marketing & distribution network to provide relief to the pandemic hit world. .

Market Drivers
Increase in the prevalence of chronic and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, cancer, and others is a major factor that boosts the demand for biosimilars worldwide. In the U.S., around 8% of the population suffers from autoimmune diseases, of which 78% are women.

Biologic therapies are some of the most expensive treatments in the pharmaceutical industry, apparently costing as much as $50,000 per patient per year. Biosimilar represent a significant opportunity for the patients that need advanced drugs a low cost than biologic drugs that is projected to drive the market growth.

Market Opportunities
Biopharmaceutical companies are investing a huge amount of money in R&D of advanced biosimilars. There is a high demand for more efficient and reliable biosimilar drugs for the treatment of cancer and autoimmune diseases. In addition, the presence of reimbursement policies for covering biosimilars for the treatment of serious medical conditions is expected to boost the market growth.

The cost of chronic diseases and cancer treatment is high due to expensive biologic therapies. The impact of the global recession on government budgets, particularly in the developed markets, is resulting in the implementation of cost control measures on pharmaceutical spending. Healthcare payers are looking to cut spending by using cheaper alternatives including biosimilars that is projected to drive the market growth.

Competitive Landscape
Biosimilars market is a highly consolidated market with several global players. Some of the major players operating in the market are Amgen, Sandoz -Novartis, Merck & Co., Pfizer, Eli Lilly and Company, Biogen, Teva Pharmaceuticals, Celltrion, Sanofi, Samsung Bioepis, Mylan, Fresenius Kabi, Intas Pharmaceuticals Ltd., AbbiVie, and STADA Arzneimittel AG. These companies are adopting several different strategies such as investment in R&D, M&A, collaborations, and new product launches to gain maximum revenue share in the market.

Major strategies acquired by the leading players are M&A, collaborations, new product launches, high investment in R&D, and geographical expansion. M&A and strategic collaboration helps the companies to strengthen their existing product portfolio and geographical reach. Also, it assist companies to strengthen their R&D capabilities, product pipeline, and operational network. For instance, in January 2020, Sanofi completed the acquisition of Synthorx, Inc. for US $68 per share in cash. The acquisition aligns with Sanofi’s R&D strategy to enhance their position in the area of immunology and oncology.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.

11 January 2021

Read

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever